# Bancfirst Corp: financial statements, quarterly

BANF · Nasdaq · CIK 760498 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/banf.md) · [Financials](/companies/banf/financials.md) · [Filings](/companies/banf/filings.md) · [Insiders](/companies/banf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/banf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [55.9](/filings/0000950170-23-059271.md) | [62.4 d](/filings/0000950170-24-020908.md) | [65.5](/filings/0000950170-24-054176.md) | [68.6](/filings/0000950170-24-091314.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [14.2](/filings/0000950170-24-121319.md) | [11.5 d](/filings/0001193125-26-075954.md) | [13.9](/filings/0000950170-25-067899.md) | [14.5](/filings/0000950170-25-102920.md) | [15.0](/filings/0001193125-25-271672.md) | [15.5 d](/filings/0001193125-26-075954.md) | [15.0](/filings/0001193125-26-214181.md) | [17.4](/filings/0001193125-26-339980.md) | [16.3](/filings/0001193125-25-271672.md) | [15.9 d](/filings/0001193125-26-075954.md) | [17.1](/filings/0001193125-26-214181.md) | [18.4](/filings/0001193125-26-339980.md) |
| Net income | $m | [51.0](/filings/0000950170-24-121319.md) | [48.9 d](/filings/0001193125-26-075954.md) | [50.3](/filings/0000950170-25-067899.md) | [50.6](/filings/0000950170-25-102920.md) | [58.9](/filings/0001193125-25-271672.md) | [56.5 d](/filings/0001193125-26-075954.md) | [56.1](/filings/0001193125-26-214181.md) | [62.3](/filings/0001193125-26-339980.md) | [62.7](/filings/0001193125-25-271672.md) | [59.5 d](/filings/0001193125-26-075954.md) | [63.0](/filings/0001193125-26-214181.md) | [66.7](/filings/0001193125-26-339980.md) |
| Diluted EPS | $ per share | [1.52](/filings/0000950170-24-121319.md) | not reported | [1.50](/filings/0000950170-25-067899.md) | [1.51](/filings/0000950170-25-102920.md) | [1.75](/filings/0001193125-25-271672.md) | not reported | [1.66](/filings/0001193125-26-214181.md) | [1.85](/filings/0001193125-26-339980.md) | [1.85](/filings/0001193125-25-271672.md) | not reported | [1.85](/filings/0001193125-26-214181.md) | [1.96](/filings/0001193125-26-339980.md) |
| Basic EPS | $ per share | [1.55](/filings/0000950170-24-121319.md) | not reported | [1.53](/filings/0000950170-25-067899.md) | [1.53](/filings/0000950170-25-102920.md) | [1.78](/filings/0001193125-25-271672.md) | not reported | [1.69](/filings/0001193125-26-214181.md) | [1.87](/filings/0001193125-26-339980.md) | [1.88](/filings/0001193125-25-271672.md) | not reported | [1.88](/filings/0001193125-26-214181.md) | [1.98](/filings/0001193125-26-339980.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [12.1](/filings/0000950170-23-059271.md) | [12.4](/filings/0001193125-26-075954.md) | [12.6](/filings/0000950170-25-067899.md) | [12.7](/filings/0000950170-25-102920.md) | [13.3](/filings/0001193125-25-271672.md) | [13.6](/filings/0001193125-26-075954.md) | [14.0](/filings/0001193125-26-214181.md) | [14.0](/filings/0001193125-26-339980.md) | [14.2](/filings/0001193125-25-271672.md) | [14.8](/filings/0001193125-26-339980.md) | [15.1](/filings/0001193125-26-214181.md) | [15.1](/filings/0001193125-26-339980.md) |
| Total liabilities | $bn | [10.7](/filings/0000950170-23-059271.md) | [10.9](/filings/0000950170-25-030159.md) | [11.1](/filings/0000950170-24-054176.md) | [11.2](/filings/0000950170-24-091314.md) | [11.7](/filings/0000950170-24-121319.md) | [11.9](/filings/0001193125-26-075954.md) | [12.4](/filings/0000950170-25-067899.md) | [12.3](/filings/0000950170-25-102920.md) | [12.4](/filings/0001193125-25-271672.md) | [13.0](/filings/0001193125-26-339980.md) | [13.2](/filings/0001193125-26-214181.md) | [13.1](/filings/0001193125-26-339980.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $bn | [0.0](/filings/0000950170-23-059271.md) | [0.0](/filings/0000950170-25-030159.md) | [0.0](/filings/0000950170-24-054176.md) | [0.0](/filings/0000950170-24-091314.md) | [0.0](/filings/0000950170-24-121319.md) | [0.0](/filings/0001193125-26-075954.md) | not reported | [0.0](/filings/0000950170-25-102920.md) | [0.0](/filings/0001193125-25-271672.md) | [0.0](/filings/0001193125-26-339980.md) | [0.0](/filings/0001193125-26-214181.md) | [0.0](/filings/0001193125-26-339980.md) |
| Shareholders' equity | $bn | [1.4](/filings/0000950170-24-121319.md) | [1.4](/filings/0001193125-26-075954.md) | [1.5](/filings/0000950170-25-067899.md) | [1.5](/filings/0000950170-25-102920.md) | [1.6](/filings/0001193125-25-271672.md) | [1.6](/filings/0001193125-26-075954.md) | [1.7](/filings/0001193125-26-214181.md) | [1.7](/filings/0001193125-26-339980.md) | [1.8](/filings/0001193125-25-271672.md) | [1.9](/filings/0001193125-26-339980.md) | [1.9](/filings/0001193125-26-214181.md) | [2.0](/filings/0001193125-26-339980.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [61.1 d](/filings/0000950170-24-121319.md) | [42.8 d](/filings/0001193125-26-075954.md) | [66.3](/filings/0000950170-25-067899.md) | [100 d](/filings/0000950170-25-102920.md) | [77.6 d](/filings/0001193125-25-271672.md) | [17.1 d](/filings/0001193125-26-075954.md) | [77.0](/filings/0001193125-26-214181.md) | [78.1 d](/filings/0001193125-26-339980.md) | [75.4 d](/filings/0001193125-25-271672.md) | [54.8 d](/filings/0001193125-26-075954.md) | [75.8](/filings/0001193125-26-214181.md) | [83.1 d](/filings/0001193125-26-339980.md) |
| Capital expenditure | $m | [4.7 d](/filings/0000950170-24-121319.md) | [4.8 d](/filings/0001193125-26-075954.md) | [10.3](/filings/0000950170-25-067899.md) | [6.0 d](/filings/0000950170-25-102920.md) | [5.2 d](/filings/0001193125-25-271672.md) | [15.1 d](/filings/0001193125-26-075954.md) | [11.3](/filings/0001193125-26-214181.md) | [13.7 d](/filings/0001193125-26-339980.md) | [11.7 d](/filings/0001193125-25-271672.md) | [11.5 d](/filings/0001193125-26-075954.md) | [10.8](/filings/0001193125-26-214181.md) | [9.8 d](/filings/0001193125-26-339980.md) |
| Dividends paid | $m | [13.2 d](/filings/0000950170-24-121319.md) | [14.2 d](/filings/0001193125-26-075954.md) | [14.2](/filings/0000950170-25-067899.md) | [14.2 d](/filings/0000950170-25-102920.md) | [14.2 d](/filings/0001193125-25-271672.md) | [15.2 d](/filings/0001193125-26-075954.md) | [15.3](/filings/0001193125-26-214181.md) | [15.3 d](/filings/0001193125-26-339980.md) | [15.3 d](/filings/0001193125-25-271672.md) | [16.3 d](/filings/0001193125-26-075954.md) | [16.4](/filings/0001193125-26-214181.md) | [16.5 d](/filings/0001193125-26-339980.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001193125-26-075954.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.5](/filings/0000950170-23-059271.md) | [33.5](/filings/0000950170-24-054176.md) | [33.5](/filings/0000950170-24-091314.md) | [33.5](/filings/0000950170-24-121319.md) | [33.5](/filings/0000950170-25-067899.md) | [33.5](/filings/0000950170-25-102920.md) | [33.6](/filings/0001193125-25-271672.md) | [33.8](/filings/0001193125-26-214181.md) | [33.8](/filings/0001193125-26-339980.md) | [33.9](/filings/0001193125-25-271672.md) | [34.0](/filings/0001193125-26-214181.md) | [34.1](/filings/0001193125-26-339980.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,598,745 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-339980.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.